134 related articles for article (PubMed ID: 34624561)
1. The combination of aging and chronic kidney disease leads to an exacerbated cortical porosity phenotype.
Tippen SP; Metzger CE; Swallow EA; Sacks SA; Wallace JM; Allen MR
Bone; 2022 Jan; 154():116228. PubMed ID: 34624561
[TBL] [Abstract][Full Text] [Related]
2. Elevations in Cortical Porosity Occur Prior to Significant Rise in Serum Parathyroid Hormone in Young Female Mice with Adenine-Induced CKD.
Metzger CE; Swallow EA; Allen MR
Calcif Tissue Int; 2020 Apr; 106(4):392-400. PubMed ID: 31832725
[TBL] [Abstract][Full Text] [Related]
3. Combining raloxifene and mechanical loading improves bone composition and mechanical properties in a murine model of chronic kidney disease (CKD).
Surowiec RK; Reul ON; Chowdhury NN; Rai RK; Segvich D; Tomaschke AA; Damrath J; Jacobson AM; Allen MR; Wallace JM
Bone; 2024 Jun; 183():117089. PubMed ID: 38575047
[TBL] [Abstract][Full Text] [Related]
4. Strain-specific alterations in the skeletal response to adenine-induced chronic kidney disease are associated with differences in parathyroid hormone levels.
Metzger CE; Swallow EA; Stacy AJ; Allen MR
Bone; 2021 Jul; 148():115963. PubMed ID: 33878503
[TBL] [Abstract][Full Text] [Related]
5. Cortical porosity is elevated after a single dose of zoledronate in two rodent models of chronic kidney disease.
Swallow EA; Metzger CE; Chen NX; Wallace JM; Tippen SP; Kohler R; Moe SM; Allen MR
Bone Rep; 2022 Jun; 16():101174. PubMed ID: 35252482
[TBL] [Abstract][Full Text] [Related]
6. Reversing cortical porosity: Cortical pore infilling in preclinical models of chronic kidney disease.
Metzger CE; Swallow EA; Stacy AJ; Tippen SP; Hammond MA; Chen NX; Moe SM; Allen MR
Bone; 2021 Feb; 143():115632. PubMed ID: 32927105
[TBL] [Abstract][Full Text] [Related]
7. Cortical porosity development and progression is mitigated after etelcalcetide treatment in an animal model of chronic kidney disease.
Swallow EA; Metzger CE; Newman CL; Chen NX; Moe SM; Allen MR
Bone; 2022 Apr; 157():116340. PubMed ID: 35085840
[TBL] [Abstract][Full Text] [Related]
8. Adenine-induced chronic kidney disease induces a similar skeletal phenotype in male and female C57BL/6 mice with more severe deficits in cortical bone properties of male mice.
Metzger CE; Swallow EA; Stacy AJ; Allen MR
PLoS One; 2021; 16(4):e0250438. PubMed ID: 33891630
[TBL] [Abstract][Full Text] [Related]
9. A novel murine model of combined insulin-dependent diabetes and chronic kidney disease has greater skeletal detriments than either disease individually.
Damrath JG; Metzger CE; Allen MR; Wallace JM
Bone; 2022 Dec; 165():116559. PubMed ID: 36116758
[TBL] [Abstract][Full Text] [Related]
10. Parathyroid suppression therapy normalizes chronic kidney disease-induced elevations in cortical bone vascular perfusion: a pilot study.
Aref MW; Swallow EA; Metzger CE; Chen N; Moe SM; Allen MR
Osteoporos Int; 2019 Aug; 30(8):1693-1698. PubMed ID: 31069439
[TBL] [Abstract][Full Text] [Related]
11. Ex vivo exposure to calcitonin or raloxifene improves mechanical properties of diseased bone through non-cell mediated mechanisms.
Surowiec RK; Saldivar R; Rai RK; Metzger CE; Jacobson AM; Allen MR; Wallace JM
Bone; 2023 Aug; 173():116805. PubMed ID: 37196853
[TBL] [Abstract][Full Text] [Related]
12. Effects of unfractionated heparin on renal osteodystrophy and vascular calcification in chronic kidney disease rats.
Meng Y; Zhang H; Li Y; Li Q; Zuo L
Bone; 2014 Jan; 58():168-76. PubMed ID: 24145307
[TBL] [Abstract][Full Text] [Related]
13. Increased FGF23 protects against detrimental cardio-renal consequences during elevated blood phosphate in CKD.
Clinkenbeard EL; Noonan ML; Thomas JC; Ni P; Hum JM; Aref M; Swallow EA; Moe SM; Allen MR; White KE
JCI Insight; 2019 Feb; 4(4):. PubMed ID: 30830862
[TBL] [Abstract][Full Text] [Related]
14. Compromised vertebral structural and mechanical properties associated with progressive kidney disease and the effects of traditional pharmacological interventions.
Newman CL; Chen NX; Smith E; Smith M; Brown D; Moe SM; Allen MR
Bone; 2015 Aug; 77():50-6. PubMed ID: 25892482
[TBL] [Abstract][Full Text] [Related]
15. Musculoskeletal Health Worsened from Carnitine Supplementation and Not Impacted by a Novel Individualized Treadmill Training Protocol.
Troutman AD; Srinivasan S; Metzger CE; Fallen PB; Chen N; O'Neill KD; Allen MR; Biruete A; Moe SM; Avin KG
Am J Nephrol; 2024; 55(3):369-379. PubMed ID: 38377965
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of GSK-3β increases trabecular bone volume but not cortical bone volume in adenine-induced uremic mice with severe hyperparathyroidism.
Tatsumoto N; Arioka M; Yamada S; Takahashi-Yanaga F; Tokumoto M; Tsuruya K; Kitazono T; Sasaguri T
Physiol Rep; 2016 Nov; 4(21):. PubMed ID: 27803315
[TBL] [Abstract][Full Text] [Related]
17. Androgen therapy does not prevent bone loss and arterial calcifications in male rats with chronic kidney disease.
David K; Dubois V; Verhulst A; Sommers V; Schollaert D; Deboel L; Moermans K; Carmeliet G; D'Haese P; Vanderschueren D; Claessens F; Evenepoel P; Decallonne B
J Endocrinol; 2023 Jun; 257(3):. PubMed ID: 36951580
[TBL] [Abstract][Full Text] [Related]
18. High phosphate feeding promotes mineral and bone abnormalities in mice with chronic kidney disease.
Lau WL; Linnes M; Chu EY; Foster BL; Bartley BA; Somerman MJ; Giachelli CM
Nephrol Dial Transplant; 2013 Jan; 28(1):62-9. PubMed ID: 23045434
[TBL] [Abstract][Full Text] [Related]
19. CKD Stages, Bone Metabolism Markers, and Cortical Porosity Index: Associations and Mediation Effects Analysis.
Xiong Y; He T; Wang Y; Liu WV; Hu S; Zhang Y; Wen D; Hou B; Li Y; Zhang P; Liu J; He F; Li X
Front Endocrinol (Lausanne); 2021; 12():775066. PubMed ID: 34803931
[TBL] [Abstract][Full Text] [Related]
20. Calcitriol Suppression of Parathyroid Hormone Fails to Improve Skeletal Properties in an Animal Model of Chronic Kidney Disease.
Newman CL; Tian N; Hammond MA; Wallace JM; Brown DM; Chen NX; Moe SM; Allen MR
Am J Nephrol; 2016; 43(1):20-31. PubMed ID: 26881752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
